Key parameters for encapsulating drugs in nanoparticles

One of the early, successful uses of nanoparticles has been to develop delivery vehicles capable of ferrying large amounts of water-insoluble drugs to tumors.

Abraxane, for example, uses albumin nanoparticles to deliver high concentrations of paclitaxel to breast tumors, eliminating the use of the solvent mixture that itself can be toxic enough to limit the utility of this powerful anticancer agent. As a result, patients treated with Abraxane suffer fewer side effects and improved outcomes compared to those who receive other formulations of paclitaxel.

As a means of helping researchers develop nanoparticle-based formulations of water-insoluble drugs, investigators at the University of Texas at Austin have conducted a systematic study to quantify some of the key parameters involved in forming stable nanoparticles containing maximum levels of water-insoluble drug molecules. The findings from these experiments have been published in the journal Langmuir.

Robert Williams III, Ph.D., led this study of how water-insoluble drugs become incorporated into nanoparticles. Using a variety of chemical, temperature, and mixing conditions, the investigators create nanoparticles in which drug molecules account for as much as 86% of the final weight of the drug-nanoparticle combination.

Over the course of these experiments, the researchers found, for example that slowing the formation of the nanoparticles themselves had a large, positive effect on final drug loading levels. Mixing energy also had a large effect, as did the addition of polymer stabilizers, which led to the production of smaller nanoparticles. In addition to generating experimental data that may help guide future nanoparticle drug delivery vehicles, the researchers also provide mechanistic insights that may also prove useful.

This work is detailed in a paper titled, “Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization.” This paper was published online in advance of print publication. An abstract of this paper is available at the journal’s website. View abstract.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder